A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager ImmunotherapiesGregory L. Moore, Michael Hedvat|Molecular Cancer Therapeutics|2024Cited by 17